Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$115.50
HK$2.70(2.34%)
At close: 4:00 PM EDT
HK$115.50
HK$2.70(2.34%)
Day’s Range― - ―
52-Week RangeHK$69.20 - HK$139.70
Previous CloseN/A
Volume591.20K
Average Volume (3M)640.69K
Market Cap
HK$68.38B
Enterprise ValueHK$31.73K
Total Cash (Recent Filing)HK$7.78B
Total Debt (Recent Filing)HK$238.99M
Price to Earnings (P/E)50.3
Beta1.26
Next Earnings
Nov 04, 2026Next Dividend Ex-DateN/A
Dividend Yield1.35%
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$132.74Price Target Upside14.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.52
Revenue Forecast (FY)HK$9.41B
Bulls Say, Bears Say
Bulls Say
Integrated CDMO PlatformServing customers from development through commercial manufacturing can deepen relationships and support repeat business. This integrated CDMO model also creates opportunities to retain projects as drugs advance toward approval and ongoing supply.
Very Strong Balance SheetExtremely low leverage reduces financial risk and interest burden, giving Asymchem flexibility to fund capacity, technology, and compliance investments. The strong equity base should also improve resilience if pharmaceutical demand or project timing fluctuates.
Solid Growth And ProfitabilityThe combination of reported revenue growth and positive margins indicates continued commercial scale and an economically viable operating model. A substantial gross margin provides a base for absorbing development costs while serving complex pharmaceutical projects.
Bears Say
Weak Free-cash-flow ConversionLimited conversion of accounting profit into free cash flow can constrain internally funded expansion and reduce financial flexibility. Negative recent free-cash-flow growth also suggests that working capital or investment requirements are absorbing a large share of operating cash.
Profitability Below Prior PeaksThe substantial margin decline from earlier peaks indicates that earnings power has not fully recovered or that the project mix has become less favorable. Sustained lower margins could limit earnings growth even if the underlying CDMO platform expands.
Recent Revenue Growth ModerationModerating recent revenue growth may reflect a slower project ramp or normalization after stronger periods. If this pace persists, operating leverage could be harder to achieve and the company may need continued investment to sustain expansion.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$69.20 and its highest was HK$139.70 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$68.38B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 70 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Aug 24, 2026. The company reported HK$0.35 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.35.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.495 which represents an annual dividend yield of 1.35%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.35 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went down -7.262%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$132.74 (14.93% Upside)
HK$132.74 (14.93% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
1.35%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, development, and manufacturing solutions specifically tailored for pharmaceutical and biotechnology enterprises. Their offerings are comprehensive, covering the entire lifecycle from early clinical stages through to full commercialization, including R&D and cGMP compliant production of advanced intermediates, active pharmaceutical ingredients (APIs), and finished formulations, alongside clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the sale and distribution of medicinal products, and active participation in pharmaceutical science and technology innovation. The company was founded in 1999 and maintains its headquarters in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$132.74
▲(14.93% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―